Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia

Leuk Lymphoma. 2012 Jan;53(1):169-72. doi: 10.3109/10428194.2011.608446. Epub 2011 Sep 19.

Authors

Tobias Herold, Till Seiler, Rupert Egensperger, Christoph Trumm, Manuela Bergmann, Daniel Franke, Friederike F H Mumm, Nicole Schinwald, Christian Buske, Martin Dreyling

PMID: 21812535
DOI: 10.3109/10428194.2011.608446

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antibodies, Monoclonal, Murine-Derived / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Diagnosis, Differential
Fatal Outcome
Hemianopsia / chemically induced
Hemianopsia / diagnosis
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukoencephalopathy, Progressive Multifocal / chemically induced
Leukoencephalopathy, Progressive Multifocal / diagnosis*
Male
Rituximab
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives

Substances

Antibodies, Monoclonal, Murine-Derived
Rituximab
Cyclophosphamide
Vidarabine
fludarabine